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Background
Despite the advantages over conventional invasive approaches, 
effective minimally-invasive drug delivery in the brain remains a 
major challenge
• Blood-brain barrier (BBB) limits the drug penetration in the 
brain
• Improvements in drug penetration is possible by “opening” 
the BBB using combination of :
✓ Low-intensity focused ultrasound (FUS)
✓ Ultrasound contrast agents called “microbubbles” (MBs)
• During FUS-MB enhanced BBB opening, we can monitor 
microbubble dynamics by recording their acoustic emissions 
(AE)
Figure 1. A) Combination of FUS and MB provides a physical method to 
spatially and temporally modulate the BBB permeability and improves 
the delivery of a range of therapeutic agents in the brain. B) Acoustic 
emission (AE) detection makes it possible to monitor MB dynamics.
C) Contrast-enhanced MR Image of rodent brain before and after BBB-
opening. Brighter spot on the brain indicates higher contrast agent 
penetration and thus higher BBB permeability
Our aim is to establish closed-loop methods to 
control the BBB-opening under MB-FUS, for effective 
minimally-invasive drug delivery 
Methods Results
Ultrasound-guided focused ultrasound system implemented with 
closed-loop acoustic emission controller 
Figure 2. A) Schematic of the portable 
and cost-effective ultrasound-guided 
“BBB-opening system” that is capable 
of monitoring and controlling 
microbubble’s acoustic emission B) 
Targeting accuracy of the system is 
confirmed by contrast enhanced MR 
imaging to be less than 500 μm.
Training the controller for microbubble dynamics control
Figure 3. A) Acoustic emission during 
BBB-opening sonication with constant 
pressure B) Pharmacokinetics map of 
rodent brain after BBB-opening. 
Highlighted target spot shows relatively 
high Ktrans value (high permeability / 
perfusion) after sonication. C) Acoustic 
emission and KTrans after experiments 
with varying FUS pressures tend to have 
strong positive correlation.
Controller-implemented BBB-opening
Figure 4. A) Acoustic emission after implementing controller. Targeted acoustic emission was 5.3 Log.AU for 
given figure when the achieved level was 5.21 ± 0.18 Log.AU, giving 98.2% accuracy and 3.5% of tolerance with
rise time of less than 3 seconds. B) Applied focal pressure during controlled sonication as a function of acoustic 
emission. Higher target level had ± 90 kPa of pressure volatility, while lower target level had ± 60 kPa of 
pressure volatility, indicating that higher target AE level introduces more instability than lower target AE level. C, 
D) Resulting KTrans values after controlled BBB-opening highlighted in red and blue in addition to Fig.3C. 
Controlled BBB-Opening using acoustic emissions produced reproducible and accurate KTrans values. 
Controlled BBB-opening is completely “tunable.” 
• Out methodology shows that it is possible to monitor and 
locally control the cerebrovascular microbubble dynamics
• This capability not only allows to modulate the level of drug 
delivered in the brain, but also makes this minimally-invasive 
technology completely “tunable.”
• Following the proof-of-concept experiments, this system will 
be scaled to clinical level to accelerate the clinical translation 
of this technology against a range of brain diseases, including 
Alzheimer’s and brain cancer.
Conclusions & Future Works
Acknowledgements
This work was supported by Focused Ultrasound Foundation 
Global Internship Program (2018 & 2019), and NIH/NCI 
R37CA239039.
